{"id":57163,"date":"2026-02-14T16:32:16","date_gmt":"2026-02-14T08:32:16","guid":{"rendered":"https:\/\/flcube.com\/?p=57163"},"modified":"2026-02-14T16:32:17","modified_gmt":"2026-02-14T08:32:17","slug":"findcure-bio-raises-14-5-million-series-b-to-advance-radiopharmaceutical-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57163","title":{"rendered":"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform"},"content":{"rendered":"\n

Fannkoer Biotech (Zhongshan) Co., Ltd.<\/strong> announced the completion of a Series B financing round<\/strong> exceeding RMB\u202f100 million (USD\u202f14.5 million)<\/strong>, co-led by a renowned investment institution<\/strong> and Hecheng Capital<\/strong>, with participation from Fengyang Jialu, Zhongshan Jianzhuo, and Zhongzhi Pharma<\/strong>. Existing shareholders Sheng Lianxing and Renxi Fund<\/strong> also increased their stakes<\/strong>. The proceeds will fund radiopharmaceutical platform construction<\/strong> and accelerate clinical trials<\/strong>, advancing the company’s InnoRDC (Radionuclide Drug Conjugate) pipeline<\/strong> through investigator-initiated trials (IITs)<\/strong> in ~100 cancer patients<\/strong>.<\/p>\n\n\n\n

Financing Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Findcure Bio<\/td><\/tr>
Round<\/strong><\/td>Series B<\/td><\/tr>
Amount Raised<\/strong><\/td>>RMB\u202f100 million (USD\u202f14.5 million)<\/strong><\/td><\/tr>
Co-Leads<\/strong><\/td>Renowned investment institution + Hecheng Capital<\/td><\/tr>
Other Investors<\/strong><\/td>Fengyang Jialu, Zhongshan Jianzhuo, Zhongzhi Pharma<\/td><\/tr>
Existing Shareholders<\/strong><\/td>Sheng Lianxing, Renxi Fund (increased investment)<\/td><\/tr>
Use of Proceeds<\/strong><\/td>Radiopharmaceutical platform construction; clinical trial advancement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Platform: InnoRDC<\/h2>\n\n\n\n
Feature<\/th>InnoRDC Platform<\/th>Strategic Value<\/th><\/tr><\/thead>
Technology<\/strong><\/td>Radionuclide Drug Conjugate (RDC)<\/strong><\/td>Targeted radiotherapy<\/strong> with diagnostic companion imaging<\/strong> (theranostics)<\/td><\/tr>
Competitive Framework<\/strong><\/td>Highly differentiated<\/strong> within China’s radiopharmaceutical industry<\/td>First-mover advantage<\/strong> in RDC innovation<\/strong>; platform scalability<\/strong><\/td><\/tr>
Product Pipeline<\/strong><\/td>5 products in IIT stage<\/strong><\/td>Broad oncology coverage<\/strong>; rapid clinical validation<\/strong><\/td><\/tr>
Clinical Progress<\/strong><\/td>~100 cancer patients<\/strong> enrolled to date<\/td>Early efficacy\/safety signals<\/strong>; translatable human data<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Positioning & Market Context<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
China Radiopharmaceutical Market<\/strong><\/td>>$2 billion by 2030<\/strong>; Lutathera, Pluvicto<\/strong> (Novartis) establishing proof-of-concept<\/strong>; domestic innovation gap<\/strong> creates opportunity for Findcure<\/strong><\/td><\/tr>
RDC vs. Traditional Radiopharma<\/strong><\/td>Antibody\/small molecule targeting<\/strong> + radioisotope payload<\/strong> = tumor-specific delivery<\/strong> with imaging capability<\/strong>; superior to<\/strong> non-targeted radiotherapy<\/strong><\/td><\/tr>
IIT Strategy<\/strong><\/td>Investigator-initiated trials<\/strong> enable faster, cost-efficient clinical validation<\/strong> vs. company-sponsored registration trials<\/strong>; publication-driven evidence generation<\/strong><\/td><\/tr>
Platform Construction<\/strong><\/td>In-house manufacturing<\/strong> (isotope handling, conjugation, quality control) reduces reliance on CDMOs<\/strong>; enables rapid pipeline expansion<\/strong><\/td><\/tr>
Investor Validation<\/strong><\/td>Existing shareholder follow-on<\/strong> signals confidence in platform<\/strong>; new institutional capital<\/strong> supports Series C readiness<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Development Roadmap<\/h2>\n\n\n\n
Phase<\/th>Activity<\/th>Timeline<\/th><\/tr><\/thead>
Current<\/strong><\/td>Series B close; platform facility construction initiation<\/td>Q1\u202f2026<\/td><\/tr>
Platform Build<\/strong><\/td>Radiochemistry labs; GMP manufacturing; regulatory compliance<\/td>2026-2027<\/td><\/tr>
Clinical Expansion<\/strong><\/td>IIT expansion to 200+ patients<\/strong>; registrational trial design<\/td>2026-2027<\/td><\/tr>
Pipeline Advancement<\/strong><\/td>Lead asset IND submission; additional RDC candidates to clinic<\/td>2027<\/td><\/tr>
Partnership<\/strong><\/td>Big Pharma licensing discussions; global rights monetization<\/td>Data-dependent (2027-2028)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Findcure Bio’s radiopharmaceutical platform construction, IIT clinical outcomes, and RDC pipeline advancement. Actual results may differ due to radioisotope supply constraints, regulatory requirements for radiopharmaceutical manufacturing, and competitive dynamics with Novartis and domestic radiopharma developers.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Fannkoer Biotech (Zhongshan) Co., Ltd. announced the completion of a Series B financing round exceeding…<\/p>\n","protected":false},"author":1,"featured_media":57167,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4617],"class_list":["post-57163","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-fannkoer-biotech"],"yoast_head":"\nFindcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Fannkoer Biotech (Zhongshan) Co., Ltd. announced the completion of a Series B financing round exceeding RMB\u202f100 million (USD\u202f14.5 million), co-led by a renowned investment institution and Hecheng Capital, with participation from Fengyang Jialu, Zhongshan Jianzhuo, and Zhongzhi Pharma. Existing shareholders Sheng Lianxing and Renxi Fund also increased their stakes. The proceeds will fund radiopharmaceutical platform construction and accelerate clinical trials, advancing the company's InnoRDC (Radionuclide Drug Conjugate) pipeline through investigator-initiated trials (IITs) in ~100 cancer patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57163\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform\" \/>\n<meta property=\"og:description\" content=\"Fannkoer Biotech (Zhongshan) Co., Ltd. announced the completion of a Series B financing round exceeding RMB\u202f100 million (USD\u202f14.5 million), co-led by a renowned investment institution and Hecheng Capital, with participation from Fengyang Jialu, Zhongshan Jianzhuo, and Zhongzhi Pharma. Existing shareholders Sheng Lianxing and Renxi Fund also increased their stakes. The proceeds will fund radiopharmaceutical platform construction and accelerate clinical trials, advancing the company's InnoRDC (Radionuclide Drug Conjugate) pipeline through investigator-initiated trials (IITs) in ~100 cancer patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57163\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-14T08:32:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-14T08:32:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1404.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57163#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57163\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform\",\"datePublished\":\"2026-02-14T08:32:16+00:00\",\"dateModified\":\"2026-02-14T08:32:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57163\"},\"wordCount\":394,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57163#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1404.webp\",\"keywords\":[\"Fannkoer Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57163#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57163\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57163\",\"name\":\"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57163#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57163#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1404.webp\",\"datePublished\":\"2026-02-14T08:32:16+00:00\",\"dateModified\":\"2026-02-14T08:32:17+00:00\",\"description\":\"Fannkoer Biotech (Zhongshan) Co., Ltd. announced the completion of a Series B financing round exceeding RMB\u202f100 million (USD\u202f14.5 million), co-led by a renowned investment institution and Hecheng Capital, with participation from Fengyang Jialu, Zhongshan Jianzhuo, and Zhongzhi Pharma. Existing shareholders Sheng Lianxing and Renxi Fund also increased their stakes. The proceeds will fund radiopharmaceutical platform construction and accelerate clinical trials, advancing the company's InnoRDC (Radionuclide Drug Conjugate) pipeline through investigator-initiated trials (IITs) in ~100 cancer patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57163#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57163\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57163#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1404.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1404.webp\",\"width\":1080,\"height\":608,\"caption\":\"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57163#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform - Insight, China's Pharmaceutical Industry","description":"Fannkoer Biotech (Zhongshan) Co., Ltd. announced the completion of a Series B financing round exceeding RMB\u202f100 million (USD\u202f14.5 million), co-led by a renowned investment institution and Hecheng Capital, with participation from Fengyang Jialu, Zhongshan Jianzhuo, and Zhongzhi Pharma. Existing shareholders Sheng Lianxing and Renxi Fund also increased their stakes. The proceeds will fund radiopharmaceutical platform construction and accelerate clinical trials, advancing the company's InnoRDC (Radionuclide Drug Conjugate) pipeline through investigator-initiated trials (IITs) in ~100 cancer patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57163","og_locale":"en_US","og_type":"article","og_title":"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform","og_description":"Fannkoer Biotech (Zhongshan) Co., Ltd. announced the completion of a Series B financing round exceeding RMB\u202f100 million (USD\u202f14.5 million), co-led by a renowned investment institution and Hecheng Capital, with participation from Fengyang Jialu, Zhongshan Jianzhuo, and Zhongzhi Pharma. Existing shareholders Sheng Lianxing and Renxi Fund also increased their stakes. The proceeds will fund radiopharmaceutical platform construction and accelerate clinical trials, advancing the company's InnoRDC (Radionuclide Drug Conjugate) pipeline through investigator-initiated trials (IITs) in ~100 cancer patients.","og_url":"https:\/\/flcube.com\/?p=57163","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-14T08:32:16+00:00","article_modified_time":"2026-02-14T08:32:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1404.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57163#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57163"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform","datePublished":"2026-02-14T08:32:16+00:00","dateModified":"2026-02-14T08:32:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57163"},"wordCount":394,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=57163#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1404.webp","keywords":["Fannkoer Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57163#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57163","url":"https:\/\/flcube.com\/?p=57163","name":"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=57163#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=57163#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1404.webp","datePublished":"2026-02-14T08:32:16+00:00","dateModified":"2026-02-14T08:32:17+00:00","description":"Fannkoer Biotech (Zhongshan) Co., Ltd. announced the completion of a Series B financing round exceeding RMB\u202f100 million (USD\u202f14.5 million), co-led by a renowned investment institution and Hecheng Capital, with participation from Fengyang Jialu, Zhongshan Jianzhuo, and Zhongzhi Pharma. Existing shareholders Sheng Lianxing and Renxi Fund also increased their stakes. The proceeds will fund radiopharmaceutical platform construction and accelerate clinical trials, advancing the company's InnoRDC (Radionuclide Drug Conjugate) pipeline through investigator-initiated trials (IITs) in ~100 cancer patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57163#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57163"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=57163#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1404.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1404.webp","width":1080,"height":608,"caption":"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57163#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Findcure Bio Raises $14.5 Million Series B to Advance Radiopharmaceutical Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1404.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57163"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57163\/revisions"}],"predecessor-version":[{"id":57168,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57163\/revisions\/57168"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/57167"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}